Aspectrics Establishes Professional Services Division
News Mar 09, 2007
Aspectrics, Inc., has established a Professional Services Division which will work closely with both existing and potential customers in order to create turnkey custom solutions to address their specific application requirements.
Aspectrics has chosen John Beauchaine, former VP of Sales, to head up the Professional Services Division. In his new role as VP of Applications Development and Professional Services, John will coordinate the design of new, purpose-build technologies based on customers’ input.
According to Aspectrics, John has more than 20 years’ experience in spectroscopy applications and a proven track record in creating solid foundations for new business endeavors. In his former position as VP of Sales, John set up Aspectrics sales organization and distributor network and orchestrated strategic agreements with an impressive number of OEMs and key instrument manufacturers.
John Poling will join Aspectrics in the role of new VP of World Wide Sales., taking the role vacated by John Beauchaine.
John Poling is an accomplished executive manager with extensive experience in domestic and international sales, corporate marketing and operations management in the capital equipment and high technology laboratory instrumentation markets.
Most recently, Poling held the General Manager – VP Sales & Marketing position at Buchi Analytical, a leading supplier of FT-NIR, preparative chromatography and nutrition analysis instrumentation for the pharmaceutical, nutraceutical, food, and chemical markets.
Paul H. Salsgiver, CEO at Aspectrics, comments: "The establishment of the new Professional Services Division marks the next stage in Aspectrics’ growth, coming as it does on the back of such a successful year for EP-IR. The new Professional Services Division fits into our on-going plan to support the continuing success of our business through a customer-centric philosophy."
He continued, "John Beauchaine is the ideal person to head up the new Division contributing to the advancement of our revolutionary EP-IR technology. At the same time, John Poling will continue to drive our sales organization on to even greater success."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019